Predictors of cognitive failures in cancer survivors

Czech version

Authors: V. Boleková; V. Chlebcová
Authors‘ workplace: Fakulta psychológie, Paneurópska vysoká škola, Bratislava, Slovenská republika
Published in: Klin Onkol 2023; 36(1): 45-53
Category: Original Articles
doi: https://doi.org/10.48095/ccko202345

Overview

Background: Progress in cancer diagnostic and treatment increases the probability of survival and survival time in cancer patients. Current research focuses on the quality of life of cancer survivors and the late effects of treatment, which can take the form of cognitive failures in daily life. The aim of the presented research was to examine the relationships between subjectively-reported cognitive failures and selected socio-demographic, clinical, and psychological characteristics (age, hormonal treatment, depression, anxiety, fatigue, sleep satisfaction). Patients and methods: The research sample consisted of 102 cancer survivors aged 25–79 years and a mean time since the end of the last treatment was 17.4 months (standard deviation = 15.4). The largest part of the sample consisted of breast cancer survivors (62.4%). The level of cognitive errors and failures was measured by the Cognitive Failures Questionnaire. The PHQ-9 Patient Health Questionnaire, the GAD-7 General Anxiety Disorder Scale, and the WHOQOL-BREF Quality of Life Questionnaire were used to measure depression, anxiety, and selected aspects of quality of life. Results: An increased level of cognitive failures in daily life was found in approximately one-third of cancer survivors. The overall cognitive failures score is strongly related to the level of depression and anxiety. Decreasing levels of energy and sleep satisfaction are associated with increasing cognitive failures in everyday life. The age and hormonal therapy do not significantly differentiate the level of cognitive failures. In the regression model, which explained 34.4% of the variance of subjectively-reported cognitive functioning, depression was the only significant predictor. Conclusion: The study results mention relationship between subjective evaluation of cognitive functioning and emotional experience in cancer survivors. The administration of self-reported methods for measuring cognitive failures can be helpful in clinical practice in identifying psychological distress.

Keywords:

anxiety – Quality of life – Cognition – depression – cancer survivors – cognitive failures

Sources

1. Hardy SJ, Krull KR, Wefel JS et al. Cognitive changes in cancer survivors. Am Soc Clin Oncol Educ Book 2018; 38: 795–806. doi: 10.1200/EDBK_201179.

2. Wefel JS, Kesler SR, Noll KR et al. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin 2015; 65 (2): 123–138. doi: 10.3322/caac.21258.

3. van der Willik KD, Hauptmann M, Jóźwiak K et al. Trajectories of cognitive function prior to cancer diagnosis: a population-based study. J Natl Cancer Inst 2020; 112 (5): 480–488. doi: 10.1093/jnci/djz178.

4. Fayette D, Gaherová Ľ, Kozák T et al. Chemotherapy-related cognitive impairment in patients with Hodgkin lymphoma – pathophysiology and risk factors. Klin Onkol 2017; 30 (2): 93–99. doi: 10.14735/amko201 793.

5. Dijkshoorn ABC, van Stralen HE, Sloots M et al. Prevalence of cognitive impairment and change in patients with breast cancer: a systematic review of longitudinal studies. Psychooncology 2021; 30 (5): 635–648. doi: 10.1002/pon.5623.

6. Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep 2012; 12 (3): 267–275. doi: 10.1007/s11910-012-0264-9.

7. Vardy JL, Dhillon HM, Pond GR et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol 2015; 33 (34): 4085–4092. doi: 10.1200/JCO.2015.63.0905.

8. Poppelreuter M, Weis J, Külz AK et al. Cognitive dysfunction and subjective complaints of cancer patients. A cross-sectional study in a cancer rehabilitation centre. Eur J Cancer 2004; 40 (1): 43–49. doi: 10.1016/ j.ejca.2003.08.001.

9. Vasiľková L. Impact of treatments to improve cognitive function and quality of life on cancer patients with carcinoma of the testes. Klin Onkol 2016; 29 (4): 267–273. doi: 10.14735/amko2016267.

10. Hermelink K, Untch M, Lux MP et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007; 109 (9): 1905–1913. doi: 10.1002/cncr.22610.

11. Whittaker AL, George RP, O‘Malley L. Prevalence of cognitive impairment following chemotherapy treatment for breast cancer: a systematic review and meta--analysis. Sci Rep 2022; 12 (1): 2135. doi: 10.1038/s41598-022-05682-1.

12. Hutchinson AD, Hosking JR, Kichenadasse G et al. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 2012; 38 (7): 926–934. doi: 10.1016/ j.ctrv.2012.05.002.

13. Hermelink K, Küchenhoff H, Untch M et al. Two different sides of ‚chemobrain‘: determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology 2010; 19 (12): 1321–1328. doi: 10.1002/pon.1695.

14. O‘Farrell E, Smith A, Collins B. Objective-subjective disparity in cancer-related cognitive impairment: does the use of change measures help reconcile the difference? Psychooncology 2017; 26 (10): 1667–1674. doi: 10.1002/pon.4190.

15. Dhillon HM, Tannock IF, Pond GR et al. Perceived cognitive impairment in people with colorectal cancer who do and do not receive chemotherapy. J Cancer Surviv 2018; 12 (2): 178–185. doi: 10.1007/s11764-017-0656-6.

16. Oh PJ. Predictors of cognitive decline in people with cancer undergoing chemotherapy. Eur J Oncol Nurs 2017; 27: 53–59. doi: 10.1016/j.ejon.2016.12.007.

17. Jean-Pierre P, Winters PC, Ahles TA et al. Prevalence of self-reported memory problems in adult cancer survivors: a national cross-sectional study. J Oncol Pract 2012; 8 (1): 30–34. doi: 10.1200/JOP.2011.000231.

18. Gutenkunst SL, Vardy JL, Dhillon HM et al. Correlates of cognitive impairment in adult cancer survivors who have received chemotherapy and report cognitive problems. Support Care Cancer 2021; 29 (3): 1377–1386. doi: 10.1007/s00520-020-05616-5.

19. Pullens MJ, De Vries J, Van Warmerdam LJ et al. Chemotherapy and cognitive complaints in women with breast cancer. Psychooncology 2013; 22 (8): 1783–1789. doi: 10.1002/pon.3214.

20. Iconomou G, Mega V, Koutras A et al. Prospective assessment of emotional distress, cognitive function, and quality of life in patients with cancer treated with chemotherapy. Cancer 2004; 101 (2): 404–411. doi: 10.1002/cncr.20385.

21. Tsaras K, Papathanasiou IV, Mitsi D et al. Assessment of depression and anxiety in breast cancer patients: prevalence and associated factors. Asian Pac J Cancer Prev 2018; 19 (6): 1661–1669. doi: 10.22034/APJCP.2018.19.6. 1661.

22. Ramalho M, Fontes F, Ruano L et al. Cognitive impairment in the first year after breast cancer diagnosis: a prospective cohort study. Breast 2017; 32: 173–178. doi: 10.1016/j.breast.2017.01.018.

23. Chapman B, Helmrath S, Derakshan N. Perceived cognitive functioning and its influence on emotional vulnerability in breast cancer. Health Psychol Open 2019; 6 (2): 2055102919871661. doi: 10.1177/2055102919871661.

24. Noal S, Levy C, Hardouin A et al. One-year longitudinal study of fatigue, cognitive functions, and quality of life after adjuvant radiotherapy for breast cancer. Int J Radiat Oncol Biol Phys 2011; 81 (3): 795–803. doi: 10.1016/j.ijrobp.2010.06.037.

25. Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 2007; 11 (1): 6–15. doi: 10.1016/j.ejon.2006.02.005.

26. Lycke M, Pottel L, Pottel H et al. Predictors of baseline cancer-related cognitive impairment in cancer patients scheduled for a curative treatment. Psychooncology 2017; 26 (5): 632–639. doi: 10.1002/pon.4200.

27. Vearncombe KJ, Rolfe M, Wright M et al. Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc 2009; 15 (6): 951–962. doi: 10.1017/S1355617709990567.

28. Ahles TA, Saykin AJ, Furstenberg CT et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002; 20 (2): 485–493. doi: 10.1200/JCO.2002.20.2.485.

29. Wazqar DY. Cognitive dysfunction and its predictors in adult patients with cancer receiving chemotherapy: a cross-sectional correlational study. J Nurs Res 2019; 27 (6): e56. doi: 10.1097/jnr.0000000000000340.

30. Quesnel C, Savard J, Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 2009; 116 (1): 113–123. doi: 10.1007/s10549-008-0114-2.

31. Bakoyiannis I, Tsigka EA, Perrea D et al. The impact of endocrine therapy on cognitive functions of breast cancer patients: a systematic review. Clin Drug Investig 2016; 36 (2): 109–118. doi: 10.1007/s40261-015-0364-9.

32. Schilder CM, Eggens PC, Seynaeve C et al. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 2009; 48 (1): 76–85. doi: 10.1080/02841860802314738.

33. Navarra-Ventura G, Fernandez-Gonzalo S, Serra-Blasco M et al. Cognitive failures in healthy middle-aged Spanish adults: a cross-sectional study describing magnitude categories of subjective cognitive deficits. Eur J Psychiatry 2019; 33 (3): 135–141. doi: 10.1016/j.ejpsy.2019.04.001.

34. Bridger RS, Johnsen SÅ, Brasher K. Psychometric properties of the cognitive failures questionnaire. Ergonomics 2013; 56 (10): 1515–1524. doi: 10.1080/001 40139.2013.821172.

35. Broadbent DE, Cooper PF, FitzGerald P et al. The cognitive failures questionnaire (CFQ) and its correlates. Br J Clin Psychol 1982; 21 (1): 1–16. doi: 10.1111/j.2044-8260.1982.tb01421.x.

36. Carrigan N, Barkus E. A systematic review of cognitive failures in daily life: healthy populations. Neurosci Biobehav Rev 2016; 63: 29–42. doi: 10.1016/j.neubiorev.2016.01.010.

37. Paiva GC, Fialho MB, Costa DS et al. Ecological validity of the five digit test and the oral trails test. Arq Neuropsiquiatr 2016; 74 (1): 29–34. doi: 10.1590/0004-282X20150184.

38. Jensen JH, Miskowiak KW, Purdon S et al. Screening for cognitive impairment among patients with work-related stress complaints in Denmark: validation and evaluation of objective and self-report tools. Scand J Work Environ Health 2022; 48 (1): 71–80. doi: 10.5271/sjweh.3990.

39. Wallace CJ. Confirmatory factor analysis of the cognitive failures questionnaire: evidence for dimensionality and construct validity. Pers Individ Differ 2004; 37 (2): 307–324. doi: 10.1016/J.PAID.2003.09.005.

40. Boleková V, Chlebcová V. Overenie psychometrických charakteristík Dotazníka kognitívnych zlyhaní. In: Quaere. Recenzovaný sborník příspěvků interdisciplinární mezinárodní vědecké konference doktorandů a odborných asistentů. Hradec Králové, 2020.

41. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16 (9): 606–613. doi: 10.1046/j.1525-1497.2001.01 6009606.x.

42. Spitzer RL, Kroenke K, Williams JB et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166 (10): 1092–1097. doi: 10.1001/archinte.166.10.1092.

43. World Health Organization. Programme on mental health: WHOQOL user manual, 2012 revision. World Health Organization, 1998.

44. Aaronson NK, Bullinger M, Ahmedzai S. A modular approach to quality-of-life assessment in cancer clinical trials. Recent Results Cancer Res 1988; 111: 231–249. doi: 10.1007/978-3-642-83419-6_27.

45. Lange M, Joly F, Vardy J et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol 2019; 30 (12): 1925–1940. doi: 10.1093/annonc/mdz410.

46. Eskildsen A, Andersen LP, Pedersen AD et al. Cognitive impairments in former patients with work-related stress complaints – one year later. Stress 2016; 19 (6): 559–566. doi: 10.1080/10253890.2016.1222370.

47. Dalgaard VL, Hviid Andersen J, Pedersen AD et al. Cognitive impairments and recovery in patients with work-related stress complaints – four years later. Stress 2021; 24 (3): 294–302. doi: 10.1080/10253890.2020.1797 673.

48. Pullens MJ, De Vries J, Roukema JA. Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology 2010; 19 (11): 1127–1138. doi: 10.1002/pon.1673.

49. Ng T, Dorajoo SR, Cheung YT et al. Distinct and heterogeneous trajectories of self-perceived cognitive impairment among Asian breast cancer survivors. Psychooncology 2018; 27 (4): 1185–1192. doi: 10.1002/pon.4635.

50. Vlčková I, Pavelková K, Kepák T et al. Changes of neurocognitive functions as result of cancer treatment in children and adolescents. Klin Onkol 2008; 21 (5): 294–302.

51. Derogar M, van der Schaaf M, Lagergren P. Reference values for the EORTC QLQ-C30 quality of life questionnaire in a random sample of the Swedish population. Acta Oncol 2012; 51 (1): 10–16. doi: 10.3109/0284186X.2011.614636.

52. Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors‘ reports of impact on work, social networks, and health care response. J Cancer Surviv 2009; 3 (4): 223–232. doi: 10.1007/s11764-009-0098-x.

53. Kuba K, Weißflog G, Götzea H et al. The relationship between acceptance, fatigue, and subjective cognitive impairment in hematologic cancer survivors. Int J Clin Health Psychol 2019; 19 (2): 97–106. doi: 10.1016/ j.ijchp.2018.12.001.